(Q61917171)

English

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system d

scientific article published in January 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

colorectal cancer

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Leonard B. Saltz

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Eduardo Díaz-Rubio

16

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Alfredo Falcone

21

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Charles S. Fuchs

19

object named as

Charles Fuchs

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Carsten Bokemeyer

26

object named as

Carsten Bokemeyer

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

object named as

John Zalcberg

4

1 reference

ORCID Public Data File 2021

author name string

Qian Shi

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Aimery de Gramont

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Axel Grothey

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Benoist Chibaudel

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Hans-Joachim Schmoll

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Matthew T Seymour

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Richard M Goldberg

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Cornelis J A Punt

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Paulo M Hoff

13

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Joel Randolph Hecht

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Herbert Hurwitz

15

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Rainer Porschen

17

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Niall C Tebbutt

18

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

John Souglakos

20

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Christophe Tournigand

22

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Fairooz F Kabbinavar

23

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Volker Heinemann

24

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Eric Van Cutsem

25

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Marc Buyse

27

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Daniel J Sargent

28

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Jean-Yves Douillard

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

0 references

publication date

10 November 2014

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

33

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

22-28

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progression-free survival: meaningful or simply measurable?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic O

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Detecting an overall survival benefit that is derived from progression-free survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III trials of targeted anticancer therapies: redesigning the concept

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A perspective on surrogate endpoints in controlled clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progression-free survival is a surrogate for survival in advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25385741

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2014.56.5887

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25385741%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q61917171&oldid=1589440678"